Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bonanza! -- Ignore unavailable to you. Want to Upgrade?

To: NY0001 who wrote (37)	10/31/1997 2:57:00 PM
From: s jones	Respond to of 64

Biota It has been a very busy and exciting year for Biota with our influenza drug GG167 going into Phase III Clinical Trials and the first field trials of our influenza diagnostic test kit. We have also brought new projects into our portfolio in the area of cancer, as well as advancing our existing projects in diabetes and cancer to the next stages of their development. We are undertaking research into RSV, a virus causing a very common flu-like illness in young children, and into rhinovirus, the cause of the common cold. For these projects we are using the same discovery techniques as were employed in the influenza project. All of these targets are in keeping with Biota's goal of addressing important diseases with no suitable or effective current treatment. GG167 - The Influenza Therapeutic Biota is pleased to advise that the Southern Hemisphere Phase III clinical trials of GG167, conducted by our partner Glaxo Wellcome Australia, are now complete. A total of 455 patients with a clinical diagnosis of influenza were enrolled, well in excess of the target number of 350. Analysis of the data from the study is now under way. This Southern Hemisphere trial is part of a comprehensive world-wide Phase III programme which includes two separate pivotal proof of efficacy studies which commence in the Northern Hemisphere this month. This continued progress, and the positive results of earlier Phase II trials give us encouragement that the goal of filing for market approval towards the end of next year should be met. Point of Care Influenza Diagnostic Over 100 patients with a clinical diagnosis of influenza have been enrolled into a pilot study of the influenza diagnostic test kit. This study was carried out in Adelaide, in conjunction with our development partner BioStar, Inc of Boulder, Colorado and compared the rapid, on the spot test to existing laboratory methods which require several days to generate a diagnosis. The study was conducted through 5 clinics in the Adelaide area with two scientists from BioStar working at the Institute of Medical and Veterinary Science (IMVS) Infectious Diseases Laboratories. Final analysis of samples is still in progress. Further trials will now be undertaken in the United States this forthcoming winter (1997/98), in preparation for FDA submission in 1998.

To: NY0001 who wrote (37)	10/31/1997 3:18:00 PM
From: Giuseppe Scalamogna	Read Replies (1) \| Respond to of 64

Thanks Neuro, Currently the set-up is like this. Take stocks A and B for instance. On Monday of Week 1 Stock A begins discussion and Stock B is presented as the Stock to be discussed next on Monday of Week 3. That is, we discuss stock A for 2 weeks and discussion culminates on Sunday of week 2 with final remarks and price targets. Then on Monday of Week 3 we begin discussion of Stock B and Stock C is presented for consideration on Monday of Week 5. This way, we always have something to talk about and everyone can be prepared to disucss the next stock. Currently, there is no criteria for choosing stocks, but we could just take turns on picking companies. Currently we are in Week 1 of discussion on Supergen (SUPG). On Monday, November 10, we will begin discussion on Sunpharm (SUNP). After that, Neuro it will be your turn to present a company to discuss of your choosing. Be ready to present the name on Monday, November 10, when we begin discussion of Sunpharm. If you have any questions, you can just contact me by e-mail. Otherwise I'm looking forward to your input and we're glad to have you onboard. GS